A Novel Small Molecule Allosteric Inhibitor of IL-17A from a DNA-Encoded Library
- 6 October 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (11) , 2301-2308
Abstract
A novel series of inhibitors of the interaction of IL-17A with its cognate receptor has been discovered using DNA-encoded library (DEL) technology. The lead compound (JNJ627, Compound 1) of the series occupies the interior interface of the IL-17A homodimer and disables receptor binding. The mechanism of action involves allosteric disruption of the IL-17A quaternary structure to prevent adoption of the receptor-binding conformation, rather than direct orthosteric inhibition at the receptor-binding site. Molecules of this series exhibit remarkably slow on-rate kinetics and potent inhibition of IL-17A signaling in human primary cells.Keywords
This publication has 37 references indexed in Scilit:
- Thiazole‐Based IL‐17 Inhibitors Discovered by Scaffold MorphingChemMedChem, 2025
- Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL‐17A ( LY3509754 ): A Phase I Randomized Placebo‐Controlled StudyClinical Pharmacology & Therapeutics, 2024
- Detection of Small‐Molecule Aggregation with High‐Throughput Microplate Biophysical MethodsCurrent Protocols in Chemical Biology, 2020
- Protein-protein interactions: a structural view of inhibition strategies and the IL-23/IL-17 axis2020
- Structural Insights into the Interleukin-17 Family Cytokines and Their Receptors2019
- The IL-17 Family of Cytokines in Health and DiseaseImmunity, 2019
- The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis PathogenesisClinical Reviews in Allergy & Immunology, 2018
- IL-17 Signaling: The Yin and the YangTrends in Immunology, 2017
- Apparent activity in high-throughput screening: origins of compound-dependent assay interferenceCurrent Opinion in Chemical Biology, 2010
- Screening in a spirit haunted worldDrug Discovery Today, 2006